Early Access — free while we kick the tires
EdgarHawk

Chambers Michael Andrew

Director

Director
1 filing analyzed · 1 company · Latest 2024-08-20

Companies

Company Buys Sells Direction
Sarepta Therapeutics, Inc. SRPT 3 0 Net buying

Activity

August 2024
medium
Buy
37,038 shares
$4,955,728
Significance 4/10

Chambers buys 37,038 shares for $4,955,728.14 at SRPT; holds 284,034 shares post-transaction.

Director Michael Andrew Chambers purchased 37,038 shares across 3 separate transactions on 2024-08-16, accumulating $4,955,728.14 in equity and increasing his holdings by 15.0% to 284,034 shares. The purchase prices ranged from $133.07 to $134.66, below the current price of $140.49. Chambers' prior trading activity at Sarepta shows a consistent pattern of weakness over the 90-day window—his 5 prior buys at this ticker generated no positive 90-day outcomes, with returns ranging from -22.9% to -27.7%. The company's P/E ratio of 280.98 reflects elevated valuation relative to the $6.5M net income on $362.9M quarterly revenue, and the stock remains 14.3% below its 52-week high of $163.85. This purchase represents a material commitment but occurs within a historical context where timing at this ticker has not proven favorable on the extended horizon.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access